Substituted quinoxalines as FGFR kinase inhibitors
US9856236B2 · kind B2 · utility
17Cited by
25References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2015 |
| Grant date | Jan 2, 2018 |
| Priority date | — |
| Expiry date | Sep 11, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to new quinoxaline derivative compounds of formula (I),to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.